Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26917ArticlesСтатьиResearch ArticleProblem of iron-deficiency anemia in patients with cancers: practice in using iron-containing drugsПроблема железодефицитной анемии у пациентов с онкологическими заболеваниями: практика применения железосодержащих препаратовSnegovoyA VСнеговойАнтон Владимирович

ст. науч. сотр., отд-ние изучения новых противоопухолевых лекарств (дневной стационар амбулаторной химиотерапии)

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва15062013152VOL 15, NO2 (2013)ТОМ 15, №2 (2013)657209042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26917

The continuing relevance of anemia in cancer patients is confirmed by the results of recent trials. Decreased hemoglobin levels are shown to lead to not only poorer quality of life, but also to lower survival rates in cancer patients. Today there is evidence that iron deficiency is the most common cause of anemia. This paper considers the mechanisms of iron metabolic disturbances, the diagnosis and treatment of iron deficiency. It gives the results of many clinical trials comparing the efficacy of different iron preparations.

Актуальность проблемы анемии у онкологических больных подтверждается результатами исследований, проведенных в последнее время. Показано, что снижение уровня гемоглобина приводит не только к ухудшению качества жизни, но и ухудшению показателей выживаемости онкологических больных. На сегодняшний день доказано, что дефицит железа является наиболее частой причиной развития анемии. В данной статье рассматриваются механизмы нарушения обмена железа, вопросы диагностики и лечения железодефицита. Представлены результаты многочисленных клинических исследований, сравнивающих эффективность разных препаратов железа.

canceranemiairon deficiencyerythropoietinsferric carboxymaltoseferritintransferrinраканемиядефицит железаэритропоэтиныкарбоксимальтозат железаферритинтрансферринSchrijvers D, De Samblanx H, Roila F. Erythropoiesis - stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010; 21 (Suppl. 5): 244–7.NCCN guidelines. Cancer - and chemotherapy - induced anemia. Version 1. 2013.Ludwig H, Van B.S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293–306.Aapro M, Österborg A, Gascón P et al. Prevalence and management of cancer - related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012; 23: 1954–62.Beale A.L, Penney M.D, Allison M.C. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis 2005; 7: 398–402.Kuvibidila S.R, Gauthier T, Rayford W. Serum ferritin levels and transferrin saturation in men with prostate cancer. J Natl Med Assoc 2004; 96: 641–9.Steinmetz Т, Tschechne B, Harlin O et al. Clinical experience with ferric carboxymaltose in the treatment of cancer - and chemotherapy - associated anaemia. Ann Oncol 2013; 24: 475–82.Beguin Y, Lybaert W, Bosly A. A prospective observational study exploring the impact of iron status on response to darbepoetin alfa in patients with chemotherapy induced anemia. Blood 2009; 114 (Abstr. 2007).Ludwig H, Müldür E, Endler G et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 2011; 96 (Abstr. 982).Caro J.J, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214–21.Nissenson A.R, Wade S, Goodnough T et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005; 11: 565–74.Crawford J, Cella D, Cleeland C.S et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888–95.Auerbach M, Ballard H, Trout J.R et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy - related anemia: a multicenter, open - label, randomized trial. J Clin Oncol 2004; 22: 1301–7.Weiss G, Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005; 352: 1011–23.Grotto H.Z. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 2008; 25: 12–21.Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002; 87: 1209–21.Сельчук В.Ю., Чистяков С.С., Толокнов Б.О. и др. Железодефицитная анемия: современное состояние проблемы. Рус. мед. журн. 2012; 1 (Прил).Инструкция по применению препарата «Феринжект»®.Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522–5.Kim Y.T, Kim S.W, Yoon B.S et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105: 199–204.Henry D.H. Parenteral Iron Therapy in Cancer - Associated Anemia. Hematology 2010; 351–6.Auerbach M, Silberstein P.T, Webb R.T et al. Darbepoetin alfa 300 or 500 ug once every 3 weeks with or without intravenous iron in patients with chemotherapy - induced anemia. Am J Hematol 2010; 85: 655–63.Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy - induced anemia. J Clin Oncol 2008; 26: 1611–8.Henry D.H, Dahl N.V, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231–42.Pedrazzoli P, Farris A, Del P.S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy - related anemia without iron deficiency treated with darbepoetin a. J Clin Oncol 2008; 26: 1619–25.Steensma D.P, Sloan J.A, Dakhil S.R et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy - associated anemia. J Clin Oncol 2011; 29: 97–105.Beguin Y, Maertens J, de Prijck B et al. Darbepoetin - a and I.V.iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial [abstr.]. Blood 2008; 112: 54.Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627–32.Gafter-Gvili A, Rozen-Zvi B, Vidal L et al. Intravenous iron supplementation for the treatment of cancer - related anemia – systematic review and meta - analysis of randomized controlled trials. Acta Oncol 2013; 52 (1): 18–29.Petrelli F, Borgonovo K, Cabiddu M et al. Addition of iron to erythropoiesis - stimulating agents in cancer patients: a meta - analysis of randomized trials. J Cancer Res Clin Oncol 2012; 138: 179–87.Инструкция по применению препарата КосмоФер®.Моисеев С.В. Железе карбоксимальтозат (Феринжект®) – новый препарат для лечения железодефицитной анемии. Клин. фармакология и терапия. 2012; 21 (12): 2–7.Инструкция по применению препарата Венофер®.Steinmetz H.T, Tsamaloukas A, Schmitz S et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2011; 19: 261–9.